Which has stronger earnings and valuation, INMD or WRBY?

InMode has higher earnings, but lower revenue than Warby Parker. InMode is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.41 $93.83M $1.36 11.40 Warby Parker $871.91M 3.06 $1.64M $0.02 1,244.05

Is INMD or WRBY more profitable?

InMode has a net margin of 23.27% compared to Warby Parker's net margin of 0.15%. InMode's return on equity of 13.47% beat Warby Parker's return on equity. Company Net Margins Return on Equity Return on Assets InMode 23.27% 13.47% 11.95% Warby Parker 0.15% 2.30% 1.18%

Does the media favor INMD or WRBY?

In the previous week, Warby Parker had 1 more articles in the media than InMode. MarketBeat recorded 5 mentions for Warby Parker and 4 mentions for InMode. Warby Parker's average media sentiment score of 0.43 beat InMode's score of 0.11 indicating that Warby Parker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Warby Parker 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, INMD or ESTA?

InMode has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.41 $93.83M $1.36 11.40 Establishment Labs $211.08M 13.04 -$51.06M -$1.49 N/A

Is INMD or ESTA more profitable?

InMode has a net margin of 23.27% compared to Establishment Labs' net margin of -19.05%. InMode's return on equity of 13.47% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets InMode 23.27% 13.47% 11.95% Establishment Labs -19.05% -218.77% -12.31%

Does the media refer more to INMD or ESTA?

In the previous week, InMode had 1 more articles in the media than Establishment Labs. MarketBeat recorded 4 mentions for InMode and 3 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.16 beat InMode's score of 0.11 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Establishment Labs 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, INMD or TMDX?

TransMedics Group has higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.41 $93.83M $1.36 11.40 TransMedics Group $605.49M 4.17 $190.29M $4.40 16.60

Does the media favor INMD or TMDX?

In the previous week, InMode had 2 more articles in the media than TransMedics Group. MarketBeat recorded 4 mentions for InMode and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.62 beat InMode's score of 0.11 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TransMedics Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, INMD or LMAT?

InMode has higher revenue and earnings than LeMaitre Vascular. InMode is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.41 $93.83M $1.36 11.40 LeMaitre Vascular $249.60M 9.30 $57.73M $2.71 37.49

Does the media favor INMD or LMAT?

In the previous week, LeMaitre Vascular had 4 more articles in the media than InMode. MarketBeat recorded 8 mentions for LeMaitre Vascular and 4 mentions for InMode. LeMaitre Vascular's average media sentiment score of 0.75 beat InMode's score of 0.11 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LeMaitre Vascular 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, AXGN or INMD?

InMode has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 9.29 -$15.70M -$0.64 N/A InMode $370.49M 2.41 $93.83M $1.36 11.40

Is AXGN or INMD more profitable?

InMode has a net margin of 23.27% compared to AxoGen's net margin of -13.21%. InMode's return on equity of 13.47% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% InMode 23.27% 13.47% 11.95%

Does the media prefer AXGN or INMD?

In the previous week, AxoGen had 2 more articles in the media than InMode. MarketBeat recorded 6 mentions for AxoGen and 4 mentions for InMode. AxoGen's average media sentiment score of 0.59 beat InMode's score of 0.11 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive InMode 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

InMode (INMD) Competitors

$15.50 +0.04 (+0.23%)

As of 12:08 PM Eastern

Compare

INMD vs. WRBY, ESTA, TMDX, LMAT, and AXGN

Should you buy InMode stock or one of its competitors? MarketBeat compares InMode with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InMode include Warby Parker (WRBY), Establishment Labs (ESTA), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry.

How does InMode compare to Warby Parker?

InMode (NASDAQ:INMD) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

InMode currently has a consensus target price of $16.00, indicating a potential upside of 3.19%. Warby Parker has a consensus target price of $29.82, indicating a potential upside of 19.84%. Given Warby Parker's stronger consensus rating and higher possible upside, analysts clearly believe Warby Parker is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67

InMode has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market. Comparatively, Warby Parker has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

In the previous week, Warby Parker had 1 more articles in the media than InMode. MarketBeat recorded 5 mentions for Warby Parker and 4 mentions for InMode. Warby Parker's average media sentiment score of 0.43 beat InMode's score of 0.11 indicating that Warby Parker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Warby Parker	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InMode has a net margin of 23.27% compared to Warby Parker's net margin of 0.15%. InMode's return on equity of 13.47% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
Warby Parker	0.15%	2.30%	1.18%

68.0% of InMode shares are owned by institutional investors. Comparatively, 93.2% of Warby Parker shares are owned by institutional investors. 6.9% of InMode shares are owned by company insiders. Comparatively, 16.8% of Warby Parker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

InMode has higher earnings, but lower revenue than Warby Parker. InMode is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.41	$93.83M	$1.36	11.40
Warby Parker	$871.91M	3.06	$1.64M	$0.02	1,244.05

Summary

Warby Parker beats InMode on 10 of the 15 factors compared between the two stocks.

How does InMode compare to Establishment Labs?

InMode (NASDAQ:INMD) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

InMode has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.41	$93.83M	$1.36	11.40
Establishment Labs	$211.08M	13.04	-$51.06M	-$1.49	N/A

InMode has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

InMode currently has a consensus price target of $16.00, indicating a potential upside of 3.19%. Establishment Labs has a consensus price target of $90.43, indicating a potential downside of 3.30%. Given InMode's higher possible upside, analysts plainly believe InMode is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, InMode had 1 more articles in the media than Establishment Labs. MarketBeat recorded 4 mentions for InMode and 3 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.16 beat InMode's score of 0.11 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Establishment Labs	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InMode has a net margin of 23.27% compared to Establishment Labs' net margin of -19.05%. InMode's return on equity of 13.47% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
Establishment Labs	-19.05%	-218.77%	-12.31%

68.0% of InMode shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 6.9% of InMode shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

InMode beats Establishment Labs on 10 of the 16 factors compared between the two stocks.

How does InMode compare to TransMedics Group?

InMode (NASDAQ:INMD) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

68.0% of InMode shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 6.9% of InMode shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

TransMedics Group has a net margin of 27.04% compared to InMode's net margin of 23.27%. TransMedics Group's return on equity of 22.38% beat InMode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
TransMedics Group	27.04%	22.38%	8.46%

TransMedics Group has higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.41	$93.83M	$1.36	11.40
TransMedics Group	$605.49M	4.17	$190.29M	$4.40	16.60

InMode has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

InMode presently has a consensus target price of $16.00, suggesting a potential upside of 3.19%. TransMedics Group has a consensus target price of $134.50, suggesting a potential upside of 84.19%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, InMode had 2 more articles in the media than TransMedics Group. MarketBeat recorded 4 mentions for InMode and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.62 beat InMode's score of 0.11 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransMedics Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

TransMedics Group beats InMode on 12 of the 16 factors compared between the two stocks.

How does InMode compare to LeMaitre Vascular?

InMode (NASDAQ:INMD) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

InMode has higher revenue and earnings than LeMaitre Vascular. InMode is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.41	$93.83M	$1.36	11.40
LeMaitre Vascular	$249.60M	9.30	$57.73M	$2.71	37.49

InMode has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

LeMaitre Vascular has a net margin of 24.35% compared to InMode's net margin of 23.27%. LeMaitre Vascular's return on equity of 15.36% beat InMode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
LeMaitre Vascular	24.35%	15.36%	9.78%

68.0% of InMode shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 6.9% of InMode shares are held by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, LeMaitre Vascular had 4 more articles in the media than InMode. MarketBeat recorded 8 mentions for LeMaitre Vascular and 4 mentions for InMode. LeMaitre Vascular's average media sentiment score of 0.75 beat InMode's score of 0.11 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LeMaitre Vascular	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InMode currently has a consensus price target of $16.00, indicating a potential upside of 3.19%. LeMaitre Vascular has a consensus price target of $112.60, indicating a potential upside of 10.83%. Given LeMaitre Vascular's stronger consensus rating and higher probable upside, analysts plainly believe LeMaitre Vascular is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

LeMaitre Vascular beats InMode on 12 of the 16 factors compared between the two stocks.

How does InMode compare to AxoGen?

AxoGen (NASDAQ:AXGN) and InMode (NASDAQ:INMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

InMode has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.29	-$15.70M	-$0.64	N/A
InMode	$370.49M	2.41	$93.83M	$1.36	11.40

AxoGen has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, InMode has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

AxoGen currently has a consensus price target of $46.50, suggesting a potential upside of 18.16%. InMode has a consensus price target of $16.00, suggesting a potential upside of 3.19%. Given AxoGen's stronger consensus rating and higher probable upside, analysts clearly believe AxoGen is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InMode has a net margin of 23.27% compared to AxoGen's net margin of -13.21%. InMode's return on equity of 13.47% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
InMode	23.27%	13.47%	11.95%

80.3% of AxoGen shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, AxoGen had 2 more articles in the media than InMode. MarketBeat recorded 6 mentions for AxoGen and 4 mentions for InMode. AxoGen's average media sentiment score of 0.59 beat InMode's score of 0.11 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
InMode	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InMode beats AxoGen on 9 of the 16 factors compared between the two stocks.

Get InMode News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMD vs. The Competition

Export

Metric	InMode	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$891.23M	$8.67B	$6.82B	$12.38B
Dividend Yield	N/A	2.49%	2.67%	9.36%
P/E Ratio	11.40	16.08	27.14	24.04
Price / Sales	2.41	6.84	574.10	112.77
Price / Cash	10.37	18.55	29.05	48.09
Price / Book	1.44	3.26	10.67	6.17
Net Income	$93.83M	$228.02M	$3.59B	$331.75M
7 Day Performance	2.34%	-2.62%	-1.65%	-1.52%
1 Month Performance	15.71%	-1.76%	1.01%	-1.24%
1 Year Performance	11.55%	-0.34%	24.41%	17.64%

InMode Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMD InMode	1.7476 of 5 stars	$15.51 +0.2%	$16.00 +3.2%	+11.3%	$891.23M	$370.49M	11.40	480	Upcoming Earnings
WRBY Warby Parker	3.4096 of 5 stars	$27.47 -5.4%	$29.82 +8.6%	+10.6%	$3.11B	$871.91M	1,374.14	4,036
ESTA Establishment Labs	1.4705 of 5 stars	$87.90 -0.1%	$89.71 +2.1%	+122.7%	$2.59B	$211.08M	N/A	1,004	Positive News
TMDX TransMedics Group	4.5413 of 5 stars	$75.74 +6.3%	$134.50 +77.6%	-32.7%	$2.46B	$605.49M	17.21	210
LMAT LeMaitre Vascular	3.9813 of 5 stars	$100.29 -2.4%	$112.60 +12.3%	+27.4%	$2.35B	$249.60M	37.01	490

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMD) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InMode (INMD) Competitors

INMD vs. WRBY, ESTA, TMDX, LMAT, and AXGN

How does InMode compare to Warby Parker?

Summary

How does InMode compare to Establishment Labs?

Summary

How does InMode compare to TransMedics Group?

Summary

How does InMode compare to LeMaitre Vascular?

Summary

How does InMode compare to AxoGen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMD vs. The Competition

InMode Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InMode (INMD) Competitors

INMD vs. WRBY, ESTA, TMDX, LMAT, and AXGN

How does InMode compare to Warby Parker?

Do analysts rate INMD or WRBY?

Which has more risk and volatility, INMD or WRBY?

Does the media favor INMD or WRBY?

Is INMD or WRBY more profitable?

Do insiders & institutionals hold more shares of INMD or WRBY?

Which has stronger earnings and valuation, INMD or WRBY?

Summary

How does InMode compare to Establishment Labs?

Which has preferable earnings and valuation, INMD or ESTA?

Which has more risk and volatility, INMD or ESTA?

Do analysts rate INMD or ESTA?

Does the media refer more to INMD or ESTA?

Is INMD or ESTA more profitable?

Do institutionals and insiders believe in INMD or ESTA?

Summary

How does InMode compare to TransMedics Group?

Do institutionals & insiders hold more shares of INMD or TMDX?

Is INMD or TMDX more profitable?

Which has preferable earnings and valuation, INMD or TMDX?

Which has more risk & volatility, INMD or TMDX?

Do analysts recommend INMD or TMDX?

Does the media favor INMD or TMDX?

Summary

How does InMode compare to LeMaitre Vascular?

Which has stronger valuation and earnings, INMD or LMAT?

Which has more volatility & risk, INMD or LMAT?

Is INMD or LMAT more profitable?

Do insiders and institutionals believe in INMD or LMAT?

Does the media favor INMD or LMAT?

Do analysts prefer INMD or LMAT?

Summary

How does InMode compare to AxoGen?

Which has stronger valuation & earnings, AXGN or INMD?

Which has more volatility and risk, AXGN or INMD?

Do analysts rate AXGN or INMD?

Is AXGN or INMD more profitable?

Do institutionals and insiders hold more shares of AXGN or INMD?

Does the media prefer AXGN or INMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMD vs. The Competition

InMode Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools